Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur 57000, Malaysia.
Department of Pharmaceutical Sciences, College of Pharmacy & Health Sciences, Ajman University, Al-Jruf, Ajman P.O. Box 346, United Arab Emirates.
Int J Mol Sci. 2022 Aug 22;23(16):9470. doi: 10.3390/ijms23169470.
Diabetes is an endocrinological disorder with a rapidly increasing number of patients globally. Over the last few years, the alarming status of diabetes has become a pivotal factor pertaining to morbidity and mortality among the youth as well as middle-aged people. Current developments in our understanding related to autoimmune responses leading to diabetes have developed a cause for concern in the prospective usage of immunomodulatory agents to prevent diabetes. The mechanism of action of vaccines varies greatly, such as removing autoreactive T cells and inhibiting the interactions between immune cells. Currently, most developed diabetes vaccines have been tested in animal models, while only a few human trials have been completed with positive outcomes. In this review, we investigate the undergoing clinical trial studies for the development of a prototype diabetes vaccine.
糖尿病是一种内分泌失调疾病,全球患者数量迅速增加。在过去的几年中,糖尿病令人担忧的状况已成为年轻人和中年人发病率和死亡率的关键因素。目前,我们对导致糖尿病的自身免疫反应的理解的最新进展引起了人们对免疫调节剂预防糖尿病的潜在应用的关注。疫苗的作用机制差异很大,例如清除自身反应性 T 细胞和抑制免疫细胞之间的相互作用。目前,大多数已开发的糖尿病疫苗已在动物模型中进行了测试,而只有少数几项人类试验已经完成并取得了积极的结果。在这篇综述中,我们研究了正在进行的临床试验,以开发一种原型糖尿病疫苗。